In January 2023, Pacira submitted its supplemental New Drug Application, or sNDA, to the U.S. Supplemental New Drug Application Submitted for EXPAREL.The Company believes this training center is core to developing physician thought leaders and community-based clinicians wanting to stay at the forefront of opioid-sparing pain management. This state-of-the-art facility features a 125-seat adaptive lecture hall, broadcast studio and both wet and dry lab space for cadaver and other interactive workshops, as well as advanced ultrasound machines equipped with artificial intelligence training software. In January 2023, Pacira opened its second Innovation and Training Center in Houston. Second Innovation and Training Center Opened in Houston.See “Non-GAAP Financial Information” below. Full-year adjusted EBITDA of $212.7 million and fourth quarter adjusted EBITDA of $58.8 million.Fourth quarter GAAP net loss of $10.1 million or $0.22 per basic and diluted share.Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share.Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million.Stack.Ģ022 Full-Year and Fourth Quarter Financial Highlights “The need for non-opioid pain management remains a global imperative and our continued progress further solidifies our leadership role in this important work,” added Mr. In the coming year we expect to achieve a variety of value-driving milestones including growing product revenue, developing new indications for our commercial offering, advancing our clinical pipeline, improving gross margins, increasing cash flow, and pre-paying significant portions of our term loan B debt, which would further strengthen our balance sheet.” “We enter 2023 in a strong position with significant and durable cash flows that we believe will allow us to leverage our balance sheet to self-fund our growth and expansion. “2022 was a solid year for Pacira as we posted record revenue and significant adjusted EBITDA, recently surpassed our twelve millionth patient with EXPAREL, and advanced our product portfolio into new and exciting indications,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences.
(Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.
28, 2023 (GLOBE NEWSWIRE) - Pacira BioSciences, Inc. EXPAREL surpasses the 12 million patient mark. Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million. Record revenues of $667 million in 2022.
0 kommentar(er)
